Another factor is the EGFR‐T790M secondary mutation, which upregulates PD‐L1 expression in NSCLC through the PI3K/Akt, MAPK, and NF‐κB signaling pathways. This evidence concerns the gene EGFR and non-small cell lung carcinoma.